Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted

J Virol. 1997 Nov;71(11):8368-76. doi: 10.1128/JVI.71.11.8368-8376.1997.

Abstract

Cats immunized with cells infected with a primary isolate of feline immunodeficiency virus (FIV) and fixed with paraformaldehyde were challenged with cell-free or cell-associated homologous virus obtained ex vivo. Complete protection was observed in animals challenged with cell-free virus 4 months after completion of vaccination (p.v.) or with cell-associated virus 12 months p.v. In contrast, no protection was observed in cats challenged with cell-free virus 12 or 28 months p.v. or with cell-associated virus 37.5 months p.v. Prior to the 28- and 37.5-month challenges, the animals had received a booster dose of vaccine that had elicited a robust anamnestic immune response. These results show that vaccine-induced protection against ex vivo FIV is achievable but is relatively short-lived and can be difficult to boost.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / immunology*
  • Animals
  • Antigens, Viral / immunology
  • Cats
  • Cell-Free System
  • Disease Models, Animal
  • Female
  • Immunization, Secondary
  • Immunodeficiency Virus, Feline / immunology*
  • Immunologic Memory
  • RNA, Viral / analysis
  • Time Factors
  • Vaccination

Substances

  • AIDS Vaccines
  • Antigens, Viral
  • RNA, Viral